Venkataranganna M V, Gopumadhavan S, Sundaram R, Mitra S K
R&D Centre, The Himalaya Drug Company Bangalore, India.
J Ethnopharmacol. 1998 Dec;63(3):187-92. doi: 10.1016/s0378-8741(98)00089-0.
UL-409, a herbal preparation was investigated for its anti-ulcerogenic activity and possible mechanism of action in different experimental models. Oral administration of UL-409 at a dose of 600 mg/kg significantly reduced the volume of gastric secretion, total acidity and free acidity in aspirin + pylorus-ligated rats. The drug appeared to strengthen the gastric mucosal defense mechanism by significantly increasing the total carbohydrate:protein ratio in aspirin + pylorus-ligated rats. The major mechanism involved appears to be due to promotion of mucosal protection by augmenting gastric mucin activity. Pre-treatment with UL-409 showed inhibition of alcohol-induced contraction of isolated rat fundus preparation which was reversed by indomethacin suggesting a possible involvement of the cyclo-oxygenase system.
对草药制剂UL - 409在不同实验模型中的抗溃疡活性及其可能的作用机制进行了研究。以600mg/kg的剂量口服UL - 409可显著降低阿司匹林 + 幽门结扎大鼠的胃液分泌量、总酸度和游离酸度。该药物似乎通过显著提高阿司匹林 + 幽门结扎大鼠的总碳水化合物:蛋白质比率来增强胃黏膜防御机制。所涉及的主要机制似乎是通过增强胃黏液活性促进黏膜保护。用UL - 409预处理可抑制酒精诱导的离体大鼠胃底标本收缩,吲哚美辛可逆转这种抑制作用,提示环氧化酶系统可能参与其中。